GMEDMEDIUM SIGNALFINANCIAL10-K

GMED demonstrates strong operational improvement with meaningfully higher operating cash flow and gross profit expansion, while successfully reducing total liabilities following the NuVasive integration.

The substantial improvement in operating cash flow generation alongside gross profit growth indicates the company is effectively scaling its expanded operations post-merger. The significant reduction in total liabilities suggests successful debt management and integration execution, though the decline in cash reserves warrants monitoring for liquidity adequacy.

Comparing 2026-02-24 vs 2025-02-20View on EDGAR →
FINANCIAL ANALYSIS

GMED's financial profile shows robust operational momentum with operating cash flow growing 44.7% to $753.4M and gross profit expanding 34.4% to $1.0B on 16.7% revenue growth. The company substantially deleveraged by reducing total liabilities 32.1% to $729.5M while current liabilities fell 41.8%, though cash declined 32.9% to $526.2M. Overall, the metrics suggest successful post-merger integration with strong cash generation capabilities, though the reduced cash position requires attention given higher capital expenditure needs.

FINANCIAL STATEMENT CHANGES
Operating Cash Flow
Cash Flow
+44.7%
$520.6M→$753.4M

Operating cash flow surged 44.7% — exceptional cash generation, highest quality earnings signal.

Capital Expenditure
Cash Flow
+42.7%
$115.4M→$164.7M

Capital expenditure jumped 42.7% — major investment cycle underway; assess returns on deployment.

Current Liabilities
Balance Sheet
-41.8%
$855.9M→$498.5M

Current liabilities reduced — improved short-term financial position and working capital health.

Gross Profit
P&L
+34.4%
$759.1M→$1.0B

Gross profit expanding — improving pricing power or product mix shift toward higher-margin offerings.

Cash & Equivalents
Balance Sheet
-32.9%
$784.4M→$526.2M

Cash declined 32.9% — significant cash burn or deployment; verify adequacy of remaining liquidity runway.

Total Liabilities
Balance Sheet
-32.1%
$1.1B→$729.5M

Liabilities reduced 32.1% — deleveraging improves balance sheet strength and financial flexibility.

Accounts Receivable
Balance Sheet
+21.7%
$557.7M→$678.9M

Receivables grew 21.7% — monitor days sales outstanding for collection efficiency.

SG&A Expense
P&L
+20.1%
$981.0M→$1.2B

SG&A increased modestly — likely reflects growth-related hiring or sales expansion investment.

Revenue
P&L
+16.7%
$2.5B→$2.9B

Revenue growing 16.7% — solid top-line momentum, watch margins for quality of growth.

Inventory
Balance Sheet
+15.2%
$659.2M→$759.3M

Inventory built 15.2% — monitor whether demand supports this build or if write-downs may follow.

LANGUAGE CHANGES
NEW — 2026-02-24
PRIOR — 2025-02-20
ADDED
(Exact name of registrant as specified in its charter) DE LAWARE 04-3744954 (State or other jurisdiction of incorporation or organization) (I.R.S.
Market for Registrant s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities 48 I tem 6.
Except as may be required by law, we undertake no obligation to update any forward-looking statements as a result of new information, events or circumstances or other factors arising or coming to our attention after the date hereof.
With 9 product launches in 2025 and operations across 65 countries worldwide, we offer a comprehensive portfolio of innovative and differentiated technologies that are used to treat a variety of musculoskeletal conditions.
NuVasive Merger As previously disclosed, on September 1, 2023, pursuant to that certain merger agreement (the NuVasive Merger Agreement ) with NuVasive, Inc.
( NuVasive ) and Zebra Merger Sub Inc., a wholly owned subsidiary of the Company ( Zebra Merger Sub ), Zebra Merger Sub, merged with and into NuVasive, with NuVasive surviving as a wholly owned subsidiary of the Company (the NuVasive Merger ).
Nevro Merger As previously disclosed, on April 3, 2025, pursuant to the terms of that certain merger agreement (the Nevro Merger Agreement ) with Nevro Corp.
( Nevro ) and Palmer Merger Sub, Inc., a wholly owned subsidiary of the Company ( Palmer Merger Sub ), Palmer Merger Sub merged with and into Nevro (the Nevro Merger and, together with the NuVasive Merger, the NuVasive and Nevro Mergers ), with Nevro surviving as a wholly owned subsidiary of the Company.
Upon the consummation of the Nevro Merger, each issued and outstanding share of common stock of Nevro, $0.001 par value per share, was cancelled and converted into the right to receive cash in an amount equal to $5.85 per share of common stock of Nevro, without interest and subject to any applicable withholding taxes.
During the year ended December 31, 2025, international sales accounted for approximately 19.4% of our total sales.
REMOVED
(Exact name of registrant as specified in its charter ) DELAWARE 04-3744954 (State or other jurisdiction of incorporation or organization) (I.R.S.
Market for Registrant s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities 48 Item 7.
These risks and uncertainties include, but are not limited to, t he risks and costs associated with the integration of the NuVasive business and Globus Medical, Inc.
s ability to successfully integrate and achieve anticipated synergies with the NuVasive business , our ability to complete the acquisition of and successfully integrate the Nevro, Inc.
We undertake no obligation to update any forward-looking statements as a result of new information, events or circumstances or other factors arising or coming to our attention after the date hereof.
With 18 product launches in 2024 and operations across 66 countries worldwide, we offer a comprehensive portfolio of innovative and differentiated technologies that are used to treat a variety of musculoskeletal conditions.
NuVasive Merger On September 1, 2023, pursuant to that certain merger agreement (the Merger Agreement ) with NuVasive, Inc.
( Merger Sub ), Merger Sub, a wholly owned subsidiary of the Company, merged with and into NuVasive, with NuVasive surviving as a wholly owned subsidiary of the Company (the NuVasive Merger ).
During the year ended December 31, 2024, international sales accounted for approximately 20.6% of our total sales.
To achieve this goal, we employ the following business strategies: Leverage our integrated product development engine .
MORE FINANCIAL SIGNALS
CRMHIGHSalesforce significantly increased debt by 71% to $14.4B while simultaneously ac...
2026-03-02
UNHHIGHUNH's operating income plummeted 41% despite 12% revenue growth, indicating seve...
2026-03-02
PFEHIGHPfizer achieved a dramatic 87.3% reduction in total debt from $31.4B to $4.0B, r...
2026-02-26
GILDHIGHGILD dramatically increased R&D spending by 81.5% to $9.1B while introducing new...
2026-02-24
ANALYZE ANY FILING FREE

See what changed in your portfolio's filings

500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.

Try Tracenotes free →